The approval was based on the results of a clinical trial that demonstrated improved PFS in patients on lanreotide. While the median PFS in the placebo arm was 16 months, patients in the lanreotide ...

The somatostatin analogue lanreotide (Somatuline, Ipsen) is significantly better than placebo for controlling progression of many types of metastatic neuroendocrine tumors (NETs), according to the ...

Review the side-effects of Lanreotide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Lanreotide treatment for patients with later-stage autosomal dominant polycystic kidney disease ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

The reality of pancreas cancer care from access to delivery. Background: Somatostatin analogues in previous open label studies improved symptoms due to bowel obstruction in patients with peritoneal ...

A 35-year-old man had a clinical picture suggestive of the ectopic corticotropin syndrome related to a carcinoid tumor; biochemical and hormonal tests confirmed the diagnosis. Somatostatin-receptor ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

The US Food and Drug Administration (FDA) has approved lanreotide (Somatuline, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or ...

A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after ...

PARIS, FRANCE, 16 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will invest in a new state-of-the-art electronic autoinjector for Somatuline ® Autogel ® / Somatuline ® Depot ...